Physician profile
Matthew E Johnson
NPI 1952612020
$2,399.88
in general payments reported to CMS, 2019-2025
27 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $50.66 · 2021: $80.58 · 2022: $390 · 2023: $525 · 2024: $645 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.77 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $603.25 | 2019-2024 | Tagrisso |
| Mevion_medical_systems_inc | $284.51 | 2022-2023 | Pts250 |
| Reflexion Medical, INC. | $225.00 | 2022-2025 | Reflexion Medical Radiotherapy System |
| Siemens Medical Solutions USA, INC. | $171.22 | 2023 | |
| Novocure INC. | $170.68 | 2019-2023 | Optune |
| Medtronic USA, INC. | $122.12 | 2019 | |
| Brainlab, INC. | $100.00 | 2025 | Brainlab, INC. |
| Dendreon Pharmaceuticals LLC | $79.87 | 2019-2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $76.46 | 2022-2024 | Prolaris |
| Janssen Biotech, INC. | $53.17 | 2019-2023 | Tecvayli |
| Karl Storz Endoscopy-America | $52.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.32 | 2023-2025 | |
| Mylan Institutional INC. | $45.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.73 | 2022-2023 | Lynparza, Keytruda |
| Daiichi Sankyo INC. | $42.12 | 2022-2024 | Injectafer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39.21 | 2019-2022 | |
| Gt Medical Technologies, INC | $34.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.37 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $31.18 | 2022 | |
| Accuray Incorporated | $27.32 | 2019 | |
| Myovant Sciences INC. | $23.63 | 2021 | |
| Genzyme Corporation | $22.60 | 2021 | |
| Puma Biotechnology, INC. | $18.37 | 2021 | |
| Celgene Corporation | $16.09 | 2023 | Opdualag |
| Seagen INC. | $14.89 | 2023 | Tukysa |
| Neotract INC. | $11.15 | 2019 | |
| Tactile Systems Technology INC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.